Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Where Europe’s ‘BeNeLuxA’ Joint Pricing Pilot May Have Gone Wrong

Executive Summary

A more innovative approach to pricing and reimbursement arrangements is needed in the pilot BeNeLuxA joint pricing negotiations, says Eurordis head Yann Le Cam. The Netherlands and Belgium are expected to re-start the negotiations soon after a “time-out” period.

You may also be interested in...



Three EU Countries Strike Landmark Joint Zolgensma Pricing Deal

BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.

Europe’s Biggest Multi-Country Access Alliance Picks Up The Pace

The Valletta Group says that cancer drugs, treatments for autoimmune diseases, orphan medicines and biosimilars are among the products it is targeting in its joint procurement efforts.

BeNeLuxA Makes First Positive Reimbursement Decision On Biogen’s Spinraza

In a BeNeLuxA first, Belgium and the Netherlands have reached an agreement with Biogen to reimburse rare disease treatment Spinraza after joint health technology assessment and pricing negotiations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS120999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel